U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 2 of 2 results

DELAFLOXACIN

MORE DETAILS

  6315412YVF

Status:
US Approved Rx (2017)
First approved in 2017
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Klebsiella pneumoniae
2
Staphylococcus aureus
70
Haemophilus influenzae
10
Moraxella catarrhalis
10
Neisseria gonorrhoeae
5
Conditions:
Gonorrhea
30
Community-acquired bacterial pneumonia
11
Acute bacterial skin and skin structure infection
16
Delafloxacin (CAS registry number 189279-58-1) was described as WQ-3034 by Wakunaga Pharmaceutical Co., Ltd., Osaka & Hiroshima, Japan. It was first licensed in 1999 to Abbott Park, IL, and further developed as ABT-492. Delafloxacin (Baxdela), a ...

DELAFLOXACIN MEGLUMINE

MORE DETAILS

  N7V53U4U4T

Status:
US Approved Rx (2017)
First approved in 2017
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Klebsiella pneumoniae
2
Staphylococcus aureus
70
Haemophilus influenzae
10
Moraxella catarrhalis
10
Neisseria gonorrhoeae
5
Conditions:
Gonorrhea
30
Community-acquired bacterial pneumonia
11
Acute bacterial skin and skin structure infection
16
Delafloxacin (CAS registry number 189279-58-1) was described as WQ-3034 by Wakunaga Pharmaceutical Co., Ltd., Osaka & Hiroshima, Japan. It was first licensed in 1999 to Abbott Park, IL, and further developed as ABT-492. Delafloxacin (Baxdela), a ...
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966